Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission-Reference-Cited by-同舟云学术

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

Published:2019-11-25 Issue:4 Volume:34 Page:1052-1061
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pagani Ilaria S.,Dang Phuong,Saunders Verity A.,Grose Randall,Shanmuganathan Naranie,Kok Chung H.,Carne Lisa,Rwodzi Zandy,Watts Sophie,McLean Jennifer,Braley Jodi,Altamura Haley,Yeung David T.,Branford Susan,Yong Agnes S. M.,White Deborah L.,Hughes Timothy P.,Ross David M.

Funder

Department of Health | National Health and Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0647-x.pdf

Reference32 articles.

1. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.

2. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.

3. Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528–535.